Previous studies have demonstrated that the addition of an anti-angiogenesis agent, such as bevacizumab (anti-vascular endothelial growth factor), could increase the efficacy of EGFR-TKIs and cytotoxic chemotherapy in advanced EGFR-mutated NSCLC [45,46]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.